Company intelligence / Profile preview

Precigenetics, Inc.

Unknown, Unknown, Unknown

Ownership: Private
Development stage: Other

Overview

Precigenetics has developed proprietary optical technologies that enable real-time, non-destructive visualization of epigenetic changes at the single-cell level. Their COMPASS platform accelerates drug discovery by providing actionable insights into how cells adapt to disease and treatment, with an initial focus on precision oncology. No direct clinical results are reported as they are not a therapeutic developer

Therapeutic areas: Oncology
Modalities: Epigenetic analysis technologiesOptical and computational biology platforms (not direct therapeutics but enabling technology for drug discovery and precision medicine)
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Precigenetics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precigenetics, Inc..

Explore the full profile